加味四君子汤治疗恶性黑色素细胞瘤作用及机制的研究
|
摘要
目的：恶性黑色素瘤（Malignant melanoma, MM）是由黑色素细胞恶性转化形成，具有高侵袭和高转移特性的恶性肿瘤。MM因其持续增长的发病率和死亡率日益受到人们的重视，其发病率年平均增长速度为4%～6%，在近二十年中成倍增长。到目前为止，对MM的治疗主要包括手术、生物治疗、放疗、化疗和肿瘤疫苗，然而，只要MM发生转移，几乎没有任何治疗方法可以治愈。唯一由美国食品和药品管理局批准的治疗转移性黑色素瘤的药物达卡巴嗦，其完全缓解率尚未超过5%。这可能是由多药耐药(multidrug resistance，MDR)引起，引起多药耐药最主要的机制是肿瘤细胞凋亡通路障碍。因此，如何解决化疗药物的多药耐药性，进而提高黑色素瘤肿瘤细胞凋亡是现代医学丞待解决的问题。
中医学认为，中药在抗肿瘤作用中占有重要地位，尤其在抗耐药性和减毒增效方面更具有显著优势。随着相关研究的深入，业内学者认同“肺主皮毛”理论不能简单的理解为肺主管体表皮肤、粘膜、汗腺、发须等生理功能上的皮毛，而是对抗病邪时与“肌表”相似，是呼吸道和皮肤免疫功能相互影响相互协调的免疫反馈机制，大量临床观察表明肺与皮毛在发病机制和免疫机制上可能有相似之处，有人观察到湿疹性皮炎患者发病前后均患有肺部疾患；支气管哮喘患者64%患有皮肤疾病，临床同一药物既可治疗肺系病变，也可治疗皮肤疾患。有学者总结治疗肺癌最常用的中药有26味，本研究中有7味中药构成组方，其中白术、茯苓、甘草、浙贝母和莪术5味中药属于此26味中药之中，且肺癌治疗多采用以扶正为主的补气方剂，以四君子汤为基础加减使用频次最多，已有学者证明四君子汤加减对肺癌治疗疗效确切。培土生金也称补脾益肺，是治疗肺脾两虚证的一种治法。按五行相生规律肺金与脾土为子母关系，按虚则补其母的治则，运用培土生金之法，健脾胃可以益肺气，待脾气充实，健运复职，土旺则金自生，肺虚之候自去。脾肺同属太阴，主行于人身胸腹，两经密切相连，经气相通，气血相贯。现代医学研究表明，人类肿瘤特异性免疫治疗的重要物质基础是肿瘤抗原的存在，肺癌和黑色素瘤表达共同的黑色素瘤抗原(melanoma antigen, MAGE)MAGE-1和MAGE-3，提示这两种疾病可能有相似的抗肿瘤免疫应答机制。综上，从中医理论和现代医学两个层面支撑，精选四君子汤作为基础方剂，酌加治疗肺癌有效的药物，可能对治疗皮肤肿瘤有效。且现代药理学证明，贝母苷甲抑制人高转移巨细胞肺癌细胞的粘附、侵袭和迁移能力，同样土贝母苷甲对小鼠B16黑色素瘤和Lewis肺癌转移均具有抑制作用。莪术挥发油对多种癌细胞既有直接破坏作用，又能通过增强免疫系统功能发挥抗癌作用，莪术醇通过非依赖Caspase途径来介导肺癌A549细胞的凋亡，同样发现莪术水提波能够抑制黑色素瘤高转移细胞株B16的转移，可能与其能够抑制B16与细胞外基质的粘附以及降低B16的侵袭性和运动能力有关。半枝莲有增加机体免疫功能和抗肿瘤作用，对人肺巨细胞癌细胞株PG细胞端粒酶活性的影响明显下降，其提取物抗肺癌A549细胞生长。因而，本研究在四君子汤基础上，酌选浙贝母、莪术和半枝莲组成加味四君子汤治疗MM。
Bcl-2和Caspase是公认的凋亡相关基因，Bcl-2家族是凋亡抑制基因，对凋亡有抑制作用，研究表明，抑制Bcl-2蛋白的表达可以促进MM细胞凋亡。凋亡相关蛋白Caspases被激活后能促进凋亡，其中Caspase3和Caspase9的激活尤为重要，引起细胞凋亡。
基质金属蛋白酶(metalloprotease, MMP)是一个能够水解某些蛋白成分的蛋白家族，因其需要Ca~(2+)、Zn~(2+)等金属离子作为辅助因子而得名，其家族成员具有相似的结构，其中MMP2、MMP9研究的较为深入，MMPs几乎能降解细胞外基质（extracellular matrix，ECM）中的各种蛋白成分，破坏肿瘤细胞迁移侵袭的组织学屏障，在肿瘤侵袭转移中起关键性作用，从而在肿瘤迁移浸润转移中的作用日益受到重视，MMP被认为肿瘤侵袭转移过程中主要的蛋白水解酶。
转录因子核因子NF-κB (nuclear factor-kappa B, NF-κB)是由五种不同蛋白(p50, p52,p65/RelA, RelB, c-Rel)组成的二聚体。通常NF-κB二聚体与抑制蛋白IκB相结合，以无活性的形式存在于细胞浆中，当多种刺激激活IκB激酶诱导IκB蛋白水解后，NF-κB的DNA结合结构域和核定位序列暴露出来，使NF-κB转位到细胞核，诱导靶基因转录。有大量文献已明确NF-κB (p65)是Bcl-2、MMP2和MMP9正性转录调控因子，而Bcl-2的低表达可以通过诱导线粒体途径和受体途径使Caspase3和Caspase9表达升高。
本研究首先建立体外B16MM模型，利用血清药理学方法给药，利用MTT法确认加味四君子汤的最佳作用时间和最佳作用剂量；其次研究加味四君子汤对B16MM细胞凋亡的影响，以及调节凋亡相关基因Bcl-2、Caspase3和Caspase9表达；再次研究加味四君子汤对B16MM细胞迁移侵袭的影响，以及相关蛋白MMP2和MMP9的表达；最后研究可能参与调节上述蛋白表达的信号分子NF-κB的活性和蛋白表达，进一步明确加味四君子汤抗恶性黑色素瘤的机制。
材料与方法：
1.体外MM模型的制备。
2.血清药理学实验方法给药。
3.细胞增殖抑制试验即MTT法检测加味四君子汤含药血清对B16MM细胞增殖的影响。
4.应用流式细胞仪Annexin V-FITC/PI法检测加味四君子汤含药血清对B16MM细胞凋亡的影响。
5.应用细胞划痕实验和Transwell实验检测加味四君子汤含药血清对B16MM细胞迁移和侵袭的影响。
6.应用半定量RT-PCR法检测迁移和侵袭相关基因MMP2和MMP9的mRNA表达；检测抑制凋亡基因Bcl-2的mRNA表达，检测促进凋亡基因Caspase3和Caspase9的mRNA表达。
7.应用Western blot法检测迁移和侵袭相关基因MMP2和MMP9的蛋白表达；检测抑制凋亡基因Bcl-2的蛋白表达，检测促进凋亡基因Caspase3和Caspase9的蛋白表达；检测转录因子核因子NF-κB (p65)的蛋白表达。
8.不同剂量的加味四君子汤含药血清作用于B16细胞24h后，应用Trans AMTMNF-κB (p65)活性检测试剂盒检测其活性。
结果：
1.成功建立了体外MM模型。
2.成功制备加味四君子汤含药血清。
3.加味四君子汤含药血清作用后，抑制B16MM细胞增殖，作用12，24，48h，与同时间段空白对照组和血清对照组相比，以剂量依赖方式抑制B16恶性黑色素细胞增殖，中剂量加味四君子汤含药血清组24，48h抑制率为50.22%，53.81%，且48h与24h相比没有显著性变化。
4.加味四君子汤含药血清作用后，不同剂量的加味四君子汤含药血清作用于B16细胞24h后，应用Annexin V-FITC/PI双标记法检测细胞凋亡，结果表明加味四君子汤含药血清以剂量依赖方式促进B16MM细胞凋亡，各组凋亡率分别为：空白对照组(2.97±0.62)%，血清对照组(3.12±0.71)%，低剂量加味四君子汤含药血清组(7.10±0.95)%，中剂量中药组(19.70±0.98)%，高剂量中药组(25.21±1.03)%，顺铂组(21.31±1.00)%，除空白对照组与血清对照比较外，各组间比较均差异有统计学意义（P<0.01）。
5.加味四君子汤含药血清作用后，细胞划痕试验观察随着加味四君子汤含药血清剂量升高，B16细胞的迁移能力逐渐降低。但顺铂组迁移能力低于中剂量中药组，高于高剂量中药组。加味四君子汤含药血清以剂量依赖方式抑制B16细胞侵袭能力，各组穿过8μm含BD基质胶的Transwell小室的细胞个数分别是78.5±3.3个，80.3±3.5个，70.6±3.0个，44.6±1.8个，38.8±1.2个，41.5±1.5个,除空白对照组与血清对照比较外，各组间比较均差异有统计学意义（P<0.01）。
6.不同剂量的加味四君子汤含药血清作用于B16细胞24h后，应用半定量RT-PCR法方法检测Bcl-2、Caspase3、Caspase9、MMP2、MMP9mRNA的表达。结果表明，加味四君子汤含药血清以剂量依赖方式抑制Bcl-2mRNA表达，增加Caspase3和Caspase9mRNA表达，加味四君子汤含药血清作用后，B16MM细胞侵袭相关基因MMP2和MMP9的mRNA表达降低，且以剂量依赖方式抑制MMP2和MMP9mRNA表达；除空白对照组与血清对照比较外，各组间比较均差异有统计学意义（P<0.01）。
7.应用Western Blot方法检测，加味四君子汤含药血清以剂量依赖方式抑制Bcl-2蛋白表达，增加Caspase3和Caspase9蛋白表达，除空白对照组与血清对照比较外，各组间比较均差异有统计学意义（P<0.01），加味四君子汤含药血清作用后，B16MM细胞侵袭相关基因MMP2和MMP9的蛋白表达降低，除空白对照组与血清对照比较外，各组间比较均差异有统计学意义（P<0.01）。
8.加味四君子汤含药血清以剂量依赖方式抑制NF-κB(p65)蛋白表达，除空白对照组与血清对照比较外，各组间比较均差异有统计学意义（P<0.01）；加味四君子汤含药血清作用后，NF-κB (p65)活性降低，除空白对照组与血清对照比较外，各组间比较均差异有统计学意义（P<0.01）。
结论：
1.加味四君子汤对治疗肺癌有效的药物对B16MM细胞有作用。
2.加味四君子汤含药血清是通过下调凋亡抑制基因Bcl-2的表达，上调凋亡促进基因Caspase3和Caspase9表达来实现促进B16MM细胞凋亡，抑制B16MM细胞增殖。
3.加味四君子汤含药血清是通过下调MMP2和MMP9表达来实现抑制B16MM细胞迁移和侵袭。
4. NF-κB(p65)是介导加味四君子汤含药血清抑制B16恶性黑色素瘤的细胞迁移侵袭和促进凋亡的信号分子。
Malignant melanoma (Malignant melanoma, MM) is malignant transformation frommelanocytes, which is characteristics of high invasion and metastasis. The average annualincidence growth rate is4%to6%, the incidence is double in nearly two decades. So far, the MMtreatment methods are including surgery, biological therapy, radiation therapy, chemotherapy andtumor vaccine, however, as long as the MM is metastasis, any treatment almost can not cure thisdisease. The Dacarbazine drug was only approved by the U.S. Food and Drug Administration(FDA), and the complete remission rate has not been more than5%. This phenomenon may becaused by multi-drug resistant (multidrug resistance, MDR), which main mechanism is apoptosispathway handicap. Therefore, how to solve the chemotherapy drug MDR, and to increasemelanoma tumor cell apoptosis is urgent problem to be solved for the modern medicine.
In medicine, traditional Chinese medicine in the anti-tumor effect plays an important role,especially in the anti-drug resistance and attenuated efficiency aspects more significant advantage.With related research, industry scholars agree "lung skin and hair" theory can not be simplyinterpreted as the competent body surface lung skin, mucous membranes, sweat glands, hair andwhiskers and other physiological functions of fur, but when the fight Evils and "muscle table"similar to the respiratory tract and skin immune function coordinated interaction of the immunefeedback mechanism, a large number of clinical observations suggest that lung and fur inpathogenesis and immune mechanisms that may have similarities, eczema and dermatitis wasobserved in all patients before and after onset there lung disease;64%of patients suffering frombronchial asthma, skin diseases, clinical same drug either treating lung lesions, but also treat skindisorders. Some scholars have summarized the most commonly used traditional Chinesemedicine treatment of lung cancer,26flavor, this study has seven herbs constitute a group ofparties, which Atractylodes, Poria, Licorice, Fritillaria and Curcuma five herbs are among this26herbs and treatment of lung cancer to use more prescription righting based qi to Sijunzitang basedsubtraction maximum frequency of use, some academics have already proved Sijunzitangsubtraction curative treatment for lung cancer. Earth into gold, also known as Spleen Yifei, is thetreatment of lung and spleen deficiency of both a treatment method. Press the five elementsregularity lungs and spleen as picture-relations, according to his mother, then fill the rule is, useearth into gold of the law, can benefit lung spleen and stomach, to be tempered enrichment, health movement reinstatement, earth wang gold autogenous, lung deficiency of waiting sincelast. Insufficiency belong lunar, the main line of the chest and abdomen in the personal, the twoare closely linked through, communicated through the air, blood intersection. Modern medicalresearch shows that human tumor-specific immunotherapy is an important material basis for thepresence of tumor antigens, lung cancer and melanoma antigen expression in common melanoma(melanoma antigen, MAGE) MAGE-1and MAGE-3, suggesting that these two diseases mayhave similar anti-tumor immune response mechanism. In summary, the theory of Chinesemedicine and modern medicine from two levels of support, as a basis for selection of Sijunzitangprescriptions Zhuojia effective drug treatment of lung cancer may be an effective for thetreatment of skin cancer. Modern pharmacology proof, Fritillaria glycosides A inhibition ofhuman highly metastatic giant cell lung cancer cell adhesion, invasion and migration, the sameTubeimoside on mouse B16melanoma and Lewis lung metastasis were inhibited. Volatile oil onboth direct damaging effects of a variety of cancer cells, but also by enhancing the immunesystem play a role in cancer, curcumol Caspase-independent pathway through mediated apoptosisof A549cells, was also found to inhibit Curcuma water Tibo highly metastatic melanoma cellline B16of the transfer, may be related to inhibition of B16cell adhesion to extracellular matrixand reduce the invasiveness of B16and exercise capacity. Banzhilian an increase in immunefunction and anti-tumor effect on human lung giant cell carcinoma cell line PG cells telomeraseactivity decreased significantly, the extract anti-lung cancer A549cell growth. Thus, the presentstudy Sijunzitang based on the discretionary selection Fritillaria, Curcuma and flavoredcomposition banzhilian Sijunzitang treatment MM.
Chinese medicine believes that the traditional Chinese medicine play an key in antitumor,especially in anti-drug resistance, attenuation and increase efficiency. According to “LungRelating to Skin Theory”and “strengthening earth to generate metal”, Sijunzi Decoction as abasis prescriptions plus lung cancer and\or MM effective drug was selected to treat MM.
Bcl-2and Caspase were recognized as apoptosis-related genes, Bcl-2family is an apoptosisinhibiting genes, the studies have shown that inhibition of Bcl-2gene expression can promoteapoptosis of MM cells. Caspases are apoptosis-related gene for promoting apoptosis, especiallyCaspase3and Caspase9is important to induce apoptosis.
Matrix metalloproteinase (metalloprotease, MMP) is a certain family of proteins which canhydrolyze some kinds of protein component. MMPs were named as their fuction need to acofactor, as well as Ca~(2+), Zn~(2+)and other metalions.This family members have similar structures,and MMP2and MMP9were in depth research. MMPs almost degradate all protein components in the ECM, and destruct the histological barrier for tumor cell migration and invasion, and playsa critical role in tumor invasion and metastasis. Thus, it is an increase important role in tumorinvasion and metastasis. MMPS is considered to be the major proteolytic enzymes in theabove-mentioned process.
Methods:
1. Malignant melanoma model was built in vitro.
2. Plus SiJunZi Decoction was administrated by serum pharmacological method.
3. Cell proliferation inhibiting test (MTT) were used to analyse the Plus SiJunZi Decoctioncontaining serum influence on B16malignant melanoma cell proliferation.
4. Flow cytometry Annexin V-FITC/PI assay were used to analyse the Plus SiJunZi Decoctioncontaining serum influence on B16malignant melanoma cell proliferation.
5. Cell scratch test and transwell assay were used to analyse the Plus SiJunZi Decoctioncontaining serum influence on B16malignant melanoma cell migration and invasion.
6. Migration and invasion-related gene MMP2and MMP9mRNA expression were observed andanalysed by Semiquantitative RT-PCR. Inhibiting apoptotic gene Bcl-2and promoting apoptoticgenes Caspase3and Caspase9mRNA expression were also observed and analysed bySemiquantitative RT-PCR.
7. Migration and invasion-related gene MMP2and MMP9protein expression were observed andanalysed by Western Blot. Inhibiting apoptotic gene Bcl-2and promoting apoptotic genesCaspase3and Caspase9protein expression were also observed and analysed by Western Blot.The expression of NF-κB(p65) in B16malignant melanoma cell were detected and analysed byWestern Blot.
8. Trans AMTM NF-κB(p65) Kit was used to measure the activity of NF-kB.
Results：
1. Malignant melanoma model was built successfully in vitro.
2. The Plus SiJunZi Decoction containing serum was prepared successfully.
3. A time-dependent increase of inhibiting B16malignant melanoma cell proliferation by PlusSiJunZiDecoction containing serum was observed compared to blank control group, serumcontrol group in the same time period, and middle dose traditional Chinese medicine groupinhibition rate was50.22in12h and53.81in24h respectively（P<0.01），and reached the halfof inhibition rate, and half of inhibition rate in48hours period and24hours period werecompared to no significant change.
4. Plus SiJunZi Decoction containing serum promotes significantly B16malignant melanoma cell apoptosis. Flow cytometry Annexin V-FITC/PI assay were used to analyse the plus Sijunzidecoction containing serum influence on B16malignant melanoma cell apoptosis. Atime-dependent increase of inhibiting B16malignant melanoma cell apoptosis by PlusSiJunZiDecoction containing serum was observed. apoptotic rates were in each group: controlgroup (2.97±0.62)%, serum control group (3.12±0.71)%, low-dosePlus SiJunZi Decoctioncontaining serum group (7.10±0.95)%, middle dose group (19.70±0.98)%, the high dosegroup (25.21±1.03)%, cisplatin group (21.31±1.00)%. In addition to the control groupcompared with the serum control, the comparison between the groups were statisticallysignificant (P <0.01). The rate of Cisplatin group apoptosis is high than middle dose traditionalChinese medicine group, and lower than high dose traditional Chinese medicine group.
5. A time-dependent decrease of B16malignant melanoma cell migration and invasion wasobserved used cell scratch test and transwell assay by Plus SiJunZi Decoction containing serum.Each group through8μm BD Matrigel Transwell chamber cell numbers were78.5±3.3,80.3±3.5,70.6±3.0,44.6±1.8,38.8±1.2,41.5±1.5. In addition to the control group compared with the serumcontrol, the comparison between the groups were statistically significant (P <0.01).
6. RT-PCR method was used to detect Bcl-2, Caspase3, Caspase9, MMP2, MMP9mRNAexpression. The results show that, A time-dependent decrease in MMP2and MMP9mRNAexpression by Plus SiJunZi Decoction containing serum were observed, and decreases inhibitingapoptotic gene Bcl-2mRNA expression, and increases promoting apoptotic genes Caspase3andCaspase9mRNA expression.In addition to the control group compared with the serum control,the comparison between the groups were statistically significant (P <0.01).
7. Western Blot method was used to detect Bcl-2, Caspase3, Caspase9, MMP2, MMP9proteinexpression.A dose-dependent manner inhibiting Bcl-2protein expression, increasing Caspase3and Caspase9protein expression by Plus SiJunZi Decoction containing serum were observed, inaddition to the control group compared with the serum control, the comparison between thegroups were statistically significant(P<0.01). A dose-dependent manner inhibiting invasionrelated genes MMP2and MMP9protein expression were observed and analysed. In addition tothe control group compared with the serum control, the comparison between the groups werestatistically significant (P <0.01).
8. A time-dependent decrease in NF-κB(p65) protein expression in B16malignant melanoma cellwere detected. In addition to the control group compared with the serum control, the comparisonbetween the groups were statistically significant (P <0.01).The activity of NF-κB(p65) was adecrease in B16malignant melanoma cell. In addition to the control group compared with theserum control, the comparison between the groups were statistically significant(P <0.01).
Conclusions：
1. Plus Sijunzi Decoction as an efficient therapeutic pulmonary cancer prescriptions was also aneffective decoction on B16malignant melanoma.
2. Plus SiJunZi Decoction containing serum promotes significantly B16malignant melanomacell apoptosis, which can be mediated by decreasing Bcl-2expression, and increasing Caspase3and Caspase9expression. Plus SiJunZi Decoction containing serum inhibits B16malignantmelanoma cells proliferation.
3. Plus SiJunZi Decoction containing serum inhibits significantly B16malignant melanoma cellmigration and invasion, which can be mediated by decreasing MMP2and MMP9expression.
4. NF-κB(p65) signal molecule can play a key role in above-mentioned process.
中医学认为，中药在抗肿瘤作用中占有重要地位，尤其在抗耐药性和减毒增效方面更具有显著优势。随着相关研究的深入，业内学者认同“肺主皮毛”理论不能简单的理解为肺主管体表皮肤、粘膜、汗腺、发须等生理功能上的皮毛，而是对抗病邪时与“肌表”相似，是呼吸道和皮肤免疫功能相互影响相互协调的免疫反馈机制，大量临床观察表明肺与皮毛在发病机制和免疫机制上可能有相似之处，有人观察到湿疹性皮炎患者发病前后均患有肺部疾患；支气管哮喘患者64%患有皮肤疾病，临床同一药物既可治疗肺系病变，也可治疗皮肤疾患。有学者总结治疗肺癌最常用的中药有26味，本研究中有7味中药构成组方，其中白术、茯苓、甘草、浙贝母和莪术5味中药属于此26味中药之中，且肺癌治疗多采用以扶正为主的补气方剂，以四君子汤为基础加减使用频次最多，已有学者证明四君子汤加减对肺癌治疗疗效确切。培土生金也称补脾益肺，是治疗肺脾两虚证的一种治法。按五行相生规律肺金与脾土为子母关系，按虚则补其母的治则，运用培土生金之法，健脾胃可以益肺气，待脾气充实，健运复职，土旺则金自生，肺虚之候自去。脾肺同属太阴，主行于人身胸腹，两经密切相连，经气相通，气血相贯。现代医学研究表明，人类肿瘤特异性免疫治疗的重要物质基础是肿瘤抗原的存在，肺癌和黑色素瘤表达共同的黑色素瘤抗原(melanoma antigen, MAGE)MAGE-1和MAGE-3，提示这两种疾病可能有相似的抗肿瘤免疫应答机制。综上，从中医理论和现代医学两个层面支撑，精选四君子汤作为基础方剂，酌加治疗肺癌有效的药物，可能对治疗皮肤肿瘤有效。且现代药理学证明，贝母苷甲抑制人高转移巨细胞肺癌细胞的粘附、侵袭和迁移能力，同样土贝母苷甲对小鼠B16黑色素瘤和Lewis肺癌转移均具有抑制作用。莪术挥发油对多种癌细胞既有直接破坏作用，又能通过增强免疫系统功能发挥抗癌作用，莪术醇通过非依赖Caspase途径来介导肺癌A549细胞的凋亡，同样发现莪术水提波能够抑制黑色素瘤高转移细胞株B16的转移，可能与其能够抑制B16与细胞外基质的粘附以及降低B16的侵袭性和运动能力有关。半枝莲有增加机体免疫功能和抗肿瘤作用，对人肺巨细胞癌细胞株PG细胞端粒酶活性的影响明显下降，其提取物抗肺癌A549细胞生长。因而，本研究在四君子汤基础上，酌选浙贝母、莪术和半枝莲组成加味四君子汤治疗MM。
Bcl-2和Caspase是公认的凋亡相关基因，Bcl-2家族是凋亡抑制基因，对凋亡有抑制作用，研究表明，抑制Bcl-2蛋白的表达可以促进MM细胞凋亡。凋亡相关蛋白Caspases被激活后能促进凋亡，其中Caspase3和Caspase9的激活尤为重要，引起细胞凋亡。
基质金属蛋白酶(metalloprotease, MMP)是一个能够水解某些蛋白成分的蛋白家族，因其需要Ca~(2+)、Zn~(2+)等金属离子作为辅助因子而得名，其家族成员具有相似的结构，其中MMP2、MMP9研究的较为深入，MMPs几乎能降解细胞外基质（extracellular matrix，ECM）中的各种蛋白成分，破坏肿瘤细胞迁移侵袭的组织学屏障，在肿瘤侵袭转移中起关键性作用，从而在肿瘤迁移浸润转移中的作用日益受到重视，MMP被认为肿瘤侵袭转移过程中主要的蛋白水解酶。
转录因子核因子NF-κB (nuclear factor-kappa B, NF-κB)是由五种不同蛋白(p50, p52,p65/RelA, RelB, c-Rel)组成的二聚体。通常NF-κB二聚体与抑制蛋白IκB相结合，以无活性的形式存在于细胞浆中，当多种刺激激活IκB激酶诱导IκB蛋白水解后，NF-κB的DNA结合结构域和核定位序列暴露出来，使NF-κB转位到细胞核，诱导靶基因转录。有大量文献已明确NF-κB (p65)是Bcl-2、MMP2和MMP9正性转录调控因子，而Bcl-2的低表达可以通过诱导线粒体途径和受体途径使Caspase3和Caspase9表达升高。
本研究首先建立体外B16MM模型，利用血清药理学方法给药，利用MTT法确认加味四君子汤的最佳作用时间和最佳作用剂量；其次研究加味四君子汤对B16MM细胞凋亡的影响，以及调节凋亡相关基因Bcl-2、Caspase3和Caspase9表达；再次研究加味四君子汤对B16MM细胞迁移侵袭的影响，以及相关蛋白MMP2和MMP9的表达；最后研究可能参与调节上述蛋白表达的信号分子NF-κB的活性和蛋白表达，进一步明确加味四君子汤抗恶性黑色素瘤的机制。
材料与方法：
1.体外MM模型的制备。
2.血清药理学实验方法给药。
3.细胞增殖抑制试验即MTT法检测加味四君子汤含药血清对B16MM细胞增殖的影响。
4.应用流式细胞仪Annexin V-FITC/PI法检测加味四君子汤含药血清对B16MM细胞凋亡的影响。
5.应用细胞划痕实验和Transwell实验检测加味四君子汤含药血清对B16MM细胞迁移和侵袭的影响。
6.应用半定量RT-PCR法检测迁移和侵袭相关基因MMP2和MMP9的mRNA表达；检测抑制凋亡基因Bcl-2的mRNA表达，检测促进凋亡基因Caspase3和Caspase9的mRNA表达。
7.应用Western blot法检测迁移和侵袭相关基因MMP2和MMP9的蛋白表达；检测抑制凋亡基因Bcl-2的蛋白表达，检测促进凋亡基因Caspase3和Caspase9的蛋白表达；检测转录因子核因子NF-κB (p65)的蛋白表达。
8.不同剂量的加味四君子汤含药血清作用于B16细胞24h后，应用Trans AMTMNF-κB (p65)活性检测试剂盒检测其活性。
结果：
1.成功建立了体外MM模型。
2.成功制备加味四君子汤含药血清。
3.加味四君子汤含药血清作用后，抑制B16MM细胞增殖，作用12，24，48h，与同时间段空白对照组和血清对照组相比，以剂量依赖方式抑制B16恶性黑色素细胞增殖，中剂量加味四君子汤含药血清组24，48h抑制率为50.22%，53.81%，且48h与24h相比没有显著性变化。
4.加味四君子汤含药血清作用后，不同剂量的加味四君子汤含药血清作用于B16细胞24h后，应用Annexin V-FITC/PI双标记法检测细胞凋亡，结果表明加味四君子汤含药血清以剂量依赖方式促进B16MM细胞凋亡，各组凋亡率分别为：空白对照组(2.97±0.62)%，血清对照组(3.12±0.71)%，低剂量加味四君子汤含药血清组(7.10±0.95)%，中剂量中药组(19.70±0.98)%，高剂量中药组(25.21±1.03)%，顺铂组(21.31±1.00)%，除空白对照组与血清对照比较外，各组间比较均差异有统计学意义（P<0.01）。
5.加味四君子汤含药血清作用后，细胞划痕试验观察随着加味四君子汤含药血清剂量升高，B16细胞的迁移能力逐渐降低。但顺铂组迁移能力低于中剂量中药组，高于高剂量中药组。加味四君子汤含药血清以剂量依赖方式抑制B16细胞侵袭能力，各组穿过8μm含BD基质胶的Transwell小室的细胞个数分别是78.5±3.3个，80.3±3.5个，70.6±3.0个，44.6±1.8个，38.8±1.2个，41.5±1.5个,除空白对照组与血清对照比较外，各组间比较均差异有统计学意义（P<0.01）。
6.不同剂量的加味四君子汤含药血清作用于B16细胞24h后，应用半定量RT-PCR法方法检测Bcl-2、Caspase3、Caspase9、MMP2、MMP9mRNA的表达。结果表明，加味四君子汤含药血清以剂量依赖方式抑制Bcl-2mRNA表达，增加Caspase3和Caspase9mRNA表达，加味四君子汤含药血清作用后，B16MM细胞侵袭相关基因MMP2和MMP9的mRNA表达降低，且以剂量依赖方式抑制MMP2和MMP9mRNA表达；除空白对照组与血清对照比较外，各组间比较均差异有统计学意义（P<0.01）。
7.应用Western Blot方法检测，加味四君子汤含药血清以剂量依赖方式抑制Bcl-2蛋白表达，增加Caspase3和Caspase9蛋白表达，除空白对照组与血清对照比较外，各组间比较均差异有统计学意义（P<0.01），加味四君子汤含药血清作用后，B16MM细胞侵袭相关基因MMP2和MMP9的蛋白表达降低，除空白对照组与血清对照比较外，各组间比较均差异有统计学意义（P<0.01）。
8.加味四君子汤含药血清以剂量依赖方式抑制NF-κB(p65)蛋白表达，除空白对照组与血清对照比较外，各组间比较均差异有统计学意义（P<0.01）；加味四君子汤含药血清作用后，NF-κB (p65)活性降低，除空白对照组与血清对照比较外，各组间比较均差异有统计学意义（P<0.01）。
结论：
1.加味四君子汤对治疗肺癌有效的药物对B16MM细胞有作用。
2.加味四君子汤含药血清是通过下调凋亡抑制基因Bcl-2的表达，上调凋亡促进基因Caspase3和Caspase9表达来实现促进B16MM细胞凋亡，抑制B16MM细胞增殖。
3.加味四君子汤含药血清是通过下调MMP2和MMP9表达来实现抑制B16MM细胞迁移和侵袭。
4. NF-κB(p65)是介导加味四君子汤含药血清抑制B16恶性黑色素瘤的细胞迁移侵袭和促进凋亡的信号分子。
Malignant melanoma (Malignant melanoma, MM) is malignant transformation frommelanocytes, which is characteristics of high invasion and metastasis. The average annualincidence growth rate is4%to6%, the incidence is double in nearly two decades. So far, the MMtreatment methods are including surgery, biological therapy, radiation therapy, chemotherapy andtumor vaccine, however, as long as the MM is metastasis, any treatment almost can not cure thisdisease. The Dacarbazine drug was only approved by the U.S. Food and Drug Administration(FDA), and the complete remission rate has not been more than5%. This phenomenon may becaused by multi-drug resistant (multidrug resistance, MDR), which main mechanism is apoptosispathway handicap. Therefore, how to solve the chemotherapy drug MDR, and to increasemelanoma tumor cell apoptosis is urgent problem to be solved for the modern medicine.
In medicine, traditional Chinese medicine in the anti-tumor effect plays an important role,especially in the anti-drug resistance and attenuated efficiency aspects more significant advantage.With related research, industry scholars agree "lung skin and hair" theory can not be simplyinterpreted as the competent body surface lung skin, mucous membranes, sweat glands, hair andwhiskers and other physiological functions of fur, but when the fight Evils and "muscle table"similar to the respiratory tract and skin immune function coordinated interaction of the immunefeedback mechanism, a large number of clinical observations suggest that lung and fur inpathogenesis and immune mechanisms that may have similarities, eczema and dermatitis wasobserved in all patients before and after onset there lung disease;64%of patients suffering frombronchial asthma, skin diseases, clinical same drug either treating lung lesions, but also treat skindisorders. Some scholars have summarized the most commonly used traditional Chinesemedicine treatment of lung cancer,26flavor, this study has seven herbs constitute a group ofparties, which Atractylodes, Poria, Licorice, Fritillaria and Curcuma five herbs are among this26herbs and treatment of lung cancer to use more prescription righting based qi to Sijunzitang basedsubtraction maximum frequency of use, some academics have already proved Sijunzitangsubtraction curative treatment for lung cancer. Earth into gold, also known as Spleen Yifei, is thetreatment of lung and spleen deficiency of both a treatment method. Press the five elementsregularity lungs and spleen as picture-relations, according to his mother, then fill the rule is, useearth into gold of the law, can benefit lung spleen and stomach, to be tempered enrichment, health movement reinstatement, earth wang gold autogenous, lung deficiency of waiting sincelast. Insufficiency belong lunar, the main line of the chest and abdomen in the personal, the twoare closely linked through, communicated through the air, blood intersection. Modern medicalresearch shows that human tumor-specific immunotherapy is an important material basis for thepresence of tumor antigens, lung cancer and melanoma antigen expression in common melanoma(melanoma antigen, MAGE) MAGE-1and MAGE-3, suggesting that these two diseases mayhave similar anti-tumor immune response mechanism. In summary, the theory of Chinesemedicine and modern medicine from two levels of support, as a basis for selection of Sijunzitangprescriptions Zhuojia effective drug treatment of lung cancer may be an effective for thetreatment of skin cancer. Modern pharmacology proof, Fritillaria glycosides A inhibition ofhuman highly metastatic giant cell lung cancer cell adhesion, invasion and migration, the sameTubeimoside on mouse B16melanoma and Lewis lung metastasis were inhibited. Volatile oil onboth direct damaging effects of a variety of cancer cells, but also by enhancing the immunesystem play a role in cancer, curcumol Caspase-independent pathway through mediated apoptosisof A549cells, was also found to inhibit Curcuma water Tibo highly metastatic melanoma cellline B16of the transfer, may be related to inhibition of B16cell adhesion to extracellular matrixand reduce the invasiveness of B16and exercise capacity. Banzhilian an increase in immunefunction and anti-tumor effect on human lung giant cell carcinoma cell line PG cells telomeraseactivity decreased significantly, the extract anti-lung cancer A549cell growth. Thus, the presentstudy Sijunzitang based on the discretionary selection Fritillaria, Curcuma and flavoredcomposition banzhilian Sijunzitang treatment MM.
Chinese medicine believes that the traditional Chinese medicine play an key in antitumor,especially in anti-drug resistance, attenuation and increase efficiency. According to “LungRelating to Skin Theory”and “strengthening earth to generate metal”, Sijunzi Decoction as abasis prescriptions plus lung cancer and\or MM effective drug was selected to treat MM.
Bcl-2and Caspase were recognized as apoptosis-related genes, Bcl-2family is an apoptosisinhibiting genes, the studies have shown that inhibition of Bcl-2gene expression can promoteapoptosis of MM cells. Caspases are apoptosis-related gene for promoting apoptosis, especiallyCaspase3and Caspase9is important to induce apoptosis.
Matrix metalloproteinase (metalloprotease, MMP) is a certain family of proteins which canhydrolyze some kinds of protein component. MMPs were named as their fuction need to acofactor, as well as Ca~(2+), Zn~(2+)and other metalions.This family members have similar structures,and MMP2and MMP9were in depth research. MMPs almost degradate all protein components in the ECM, and destruct the histological barrier for tumor cell migration and invasion, and playsa critical role in tumor invasion and metastasis. Thus, it is an increase important role in tumorinvasion and metastasis. MMPS is considered to be the major proteolytic enzymes in theabove-mentioned process.
Methods:
1. Malignant melanoma model was built in vitro.
2. Plus SiJunZi Decoction was administrated by serum pharmacological method.
3. Cell proliferation inhibiting test (MTT) were used to analyse the Plus SiJunZi Decoctioncontaining serum influence on B16malignant melanoma cell proliferation.
4. Flow cytometry Annexin V-FITC/PI assay were used to analyse the Plus SiJunZi Decoctioncontaining serum influence on B16malignant melanoma cell proliferation.
5. Cell scratch test and transwell assay were used to analyse the Plus SiJunZi Decoctioncontaining serum influence on B16malignant melanoma cell migration and invasion.
6. Migration and invasion-related gene MMP2and MMP9mRNA expression were observed andanalysed by Semiquantitative RT-PCR. Inhibiting apoptotic gene Bcl-2and promoting apoptoticgenes Caspase3and Caspase9mRNA expression were also observed and analysed bySemiquantitative RT-PCR.
7. Migration and invasion-related gene MMP2and MMP9protein expression were observed andanalysed by Western Blot. Inhibiting apoptotic gene Bcl-2and promoting apoptotic genesCaspase3and Caspase9protein expression were also observed and analysed by Western Blot.The expression of NF-κB(p65) in B16malignant melanoma cell were detected and analysed byWestern Blot.
8. Trans AMTM NF-κB(p65) Kit was used to measure the activity of NF-kB.
Results：
1. Malignant melanoma model was built successfully in vitro.
2. The Plus SiJunZi Decoction containing serum was prepared successfully.
3. A time-dependent increase of inhibiting B16malignant melanoma cell proliferation by PlusSiJunZiDecoction containing serum was observed compared to blank control group, serumcontrol group in the same time period, and middle dose traditional Chinese medicine groupinhibition rate was50.22in12h and53.81in24h respectively（P<0.01），and reached the halfof inhibition rate, and half of inhibition rate in48hours period and24hours period werecompared to no significant change.
4. Plus SiJunZi Decoction containing serum promotes significantly B16malignant melanoma cell apoptosis. Flow cytometry Annexin V-FITC/PI assay were used to analyse the plus Sijunzidecoction containing serum influence on B16malignant melanoma cell apoptosis. Atime-dependent increase of inhibiting B16malignant melanoma cell apoptosis by PlusSiJunZiDecoction containing serum was observed. apoptotic rates were in each group: controlgroup (2.97±0.62)%, serum control group (3.12±0.71)%, low-dosePlus SiJunZi Decoctioncontaining serum group (7.10±0.95)%, middle dose group (19.70±0.98)%, the high dosegroup (25.21±1.03)%, cisplatin group (21.31±1.00)%. In addition to the control groupcompared with the serum control, the comparison between the groups were statisticallysignificant (P <0.01). The rate of Cisplatin group apoptosis is high than middle dose traditionalChinese medicine group, and lower than high dose traditional Chinese medicine group.
5. A time-dependent decrease of B16malignant melanoma cell migration and invasion wasobserved used cell scratch test and transwell assay by Plus SiJunZi Decoction containing serum.Each group through8μm BD Matrigel Transwell chamber cell numbers were78.5±3.3,80.3±3.5,70.6±3.0,44.6±1.8,38.8±1.2,41.5±1.5. In addition to the control group compared with the serumcontrol, the comparison between the groups were statistically significant (P <0.01).
6. RT-PCR method was used to detect Bcl-2, Caspase3, Caspase9, MMP2, MMP9mRNAexpression. The results show that, A time-dependent decrease in MMP2and MMP9mRNAexpression by Plus SiJunZi Decoction containing serum were observed, and decreases inhibitingapoptotic gene Bcl-2mRNA expression, and increases promoting apoptotic genes Caspase3andCaspase9mRNA expression.In addition to the control group compared with the serum control,the comparison between the groups were statistically significant (P <0.01).
7. Western Blot method was used to detect Bcl-2, Caspase3, Caspase9, MMP2, MMP9proteinexpression.A dose-dependent manner inhibiting Bcl-2protein expression, increasing Caspase3and Caspase9protein expression by Plus SiJunZi Decoction containing serum were observed, inaddition to the control group compared with the serum control, the comparison between thegroups were statistically significant(P<0.01). A dose-dependent manner inhibiting invasionrelated genes MMP2and MMP9protein expression were observed and analysed. In addition tothe control group compared with the serum control, the comparison between the groups werestatistically significant (P <0.01).
8. A time-dependent decrease in NF-κB(p65) protein expression in B16malignant melanoma cellwere detected. In addition to the control group compared with the serum control, the comparisonbetween the groups were statistically significant (P <0.01).The activity of NF-κB(p65) was adecrease in B16malignant melanoma cell. In addition to the control group compared with theserum control, the comparison between the groups were statistically significant(P <0.01).
Conclusions：
1. Plus Sijunzi Decoction as an efficient therapeutic pulmonary cancer prescriptions was also aneffective decoction on B16malignant melanoma.
2. Plus SiJunZi Decoction containing serum promotes significantly B16malignant melanomacell apoptosis, which can be mediated by decreasing Bcl-2expression, and increasing Caspase3and Caspase9expression. Plus SiJunZi Decoction containing serum inhibits B16malignantmelanoma cells proliferation.
3. Plus SiJunZi Decoction containing serum inhibits significantly B16malignant melanoma cellmigration and invasion, which can be mediated by decreasing MMP2and MMP9expression.
4. NF-κB(p65) signal molecule can play a key role in above-mentioned process.
引文
[1] Tsao H, Atkins MB, Sober AJ.Management of cutaneous melanoma. N Engl [J].Med.2004,351(10):998-1012.
[2] Stone A, Cooper J, Koenig KL, et al.A comparison of survival rates for treatment ofmelanoma metastatic to the brain[J].Cancer Invest.2004,22(4):492-497.
[3]尤建良.恶性黑色素瘤验案三则[J].四川中医.2006,24(1):69-70.
[4]杨柱,陈学习.肿瘤的中医病因病机初探[J].中国民族民间医药杂志2002,29(4):197-198.
[5]木拉提·克扎衣别克.抗肿瘤中药的分类及作用机理[J].新疆医科大学学报.2006,29(11):1102-1104.
[6]辛颖,姜新,崔俊生等．人参皂苷Rg3抑制B16黑色素瘤新生血管生成及其机制的探讨[J].中华肿瘤防治杂志.2010,17(8):590-593.
[7]阴健译.厚朴的甲醉提取物的木兰醇对体内两期致癌试验[J].国外医学.中医中药分册19,4(3):52.
[8]陈立军,朱荃.蜂王浆冻干粉含药血清对小鼠B16BL6黑色素瘤细胞增殖的影响[J].中药药理与临床.2006,22(1):44-46.
[9]顾勤,徐建亚,程罗根等.当归对黑色素瘤细胞粘附、侵袭、运动和转移能力的影响[J].中药材.2007,30(3):302-305.
[10]陈颢,陈震,屠红等.健脾理气中药对荷B16黑色素瘤小鼠肝转移的干预作用[J].上海中医药杂志.2007,41(10):79-82.
[11]张硕.乾坤宁抗肿瘤的药效学和机理研究[D].成都:成都中医药大学,2005.
[12]汤铭新,余桂清,张代钊等.复方生脉注射液治疗恶性黑色素瘤一例[J].中医杂志.1982,10(12):67-69.
[13]吴强,姚立人.脾虚对B16黑色素瘤肺转移的影响[J].安徽医科大学学报.1991,26(2):81-84.
[14]汪海英,李福安,魏全嘉.抗肿瘤中药的研究现状[J].第青海医学院学报.2008,29(4):278-282.
[15]刘晓艳,方红,羊正纲等.苦参碱对人恶性黑素瘤细胞株侵袭能力及乙酰肝素酶mRNA表达的抑制作用[J]中药材.2006,29(3):253-256.
[16]陈红,王郡甫.金荞麦提取物抑制黑色素瘤细胞穿越内皮单层的机制研究[D].山东:山东省医学科学院,2010.
[17]徐立春,陈志琳,孙振华.穿心莲提取物协同人恶黑TIL抗肿瘤的研究[J].肿瘤学报.2001,21(4):255-256.
[18]毕黎琦,李红军,张玉华．中药天花粉蛋白对黑色素瘤细胞凋亡及细胞周期的影响[J]．中国中西医结合杂志.1998,18(1):35-37.
[19]杨娴,刘汝青,杜德荣.白花蛇舌草总黄酮对黑色素瘤A375和B16细胞增殖抑制作用的研究[J].世界中西医结合杂志.2011,6(10):844-846,856.
[20]左海军,李丹,吴斌等.冬凌草的化学成分及其抗肿瘤活性[J].沈阳药科大学学报.2005,22(4):258-261.
[21]陈龙邦,王靖华,臧静等.南β-榄香烯诱导小鼠黑色素瘤B16细胞凋亡的研究[J].金陵医院学报.1992,12(1):48-49.
[22]徐立春,孙振华,陈志琳等.三棱、莪术提取物修饰的肿瘤细胞疫苗的非特异性抗瘤实验研究[J].癌症.2002,20(12):1380-1382.
[23]陈培丰,刘鲁明,陈震等.恶性肿瘤肝转移血瘀证与参三七、丹参干预作用的研究[J].浙江中医药大学学报.2007,31(5):552-553.
[24]杨庆伟,刘延庆,戴小军等.南蛇藤对鼠黑色素瘤B16BL6细胞增殖抑制及凋亡诱导作用研究[J].中药药理与临床.2008,24(3):61-63.
[25] WZ Zhao, HY Liu, SF Xu, et al．Migration and metalloproteinases determine the invasivepotential of mousemelanoma cells,but not melanin and telomerase[J].CancerLetters,2001,16(2):49-55.
[26]徐建亚,顾勤,夏卫军等.丹参对小鼠黑色素瘤细胞株B16-BL6侵袭和转移能力的影响[J].中国中医药信息杂志.2007,14(6):26-28.
[27]夏卫军,程罗根,徐建亚等.莪术对黑色素瘤细胞转移相关能力的影响[J].中药药理与临床.2007,23(2):45-47.
[28]徐建亚,顾勤,夏卫军.鸡血藤对黑色素瘤细胞黏附、侵袭、运动和转移能力的影响[J].中药材.2006,33(10):1595-1599.
[29]邱侠,杨振江,赵霞等.髓清丸对黑色素瘤VEGF MMP-2基因表达的影响[J].中医药学刊.2004,22(6):1042-1043.
[30]杨振江,赵霞,刘兵.髓清丸对裸小鼠黑色素瘤B16自发性肺转移影响的研究[J].成都中医药学报.2004,27(2):30-32.
[31]张英,张勇,黄会英.山仙颗粒对小鼠黑色素瘤肺转移中IL-2水平的影响[J].陕西中医学院学报.2004,27(3):63-64.
[32]王希胜,张英,陈光伟.山仙颗粒对小鼠黑色素瘤肺转移中NM23/NDPK水平的影响[J].陕西中医.2006,27(2):244-245.
[33]王淑美,徐晓玉,陈刚等.桃红四物汤Ⅱ号抑制小鼠B16黑色素瘤生长及VEGF,KDR／FLK-1表达[J].中国中药杂志.2005,30(23):1866-1869.
[34]郑广娟,张丹,张静.中药启乐抗肿瘤转移作用研究.医学研究通迅[J].2003,32(7):61-62.
[35]鲁向明,王仲,陈景三等.川芎嗪诱导iNOS和NO表达抗荷黑色素瘤鼠肺转移[J].2006,16(21):3208-3210.
[36]刘锦蓉,叶松柏.川芎嗪抗肿瘤转移作用及其机理.中国药理学与毒理学杂志[J].1993,7(2):149-150.
[37]王长秀,马润娣,于立坚.土贝母苷甲对小鼠B16黑色素瘤和Lewis肺癌转移的抑制作用[J].中国临床药理学与治疗学.2006,1(7):764-770.
[38]许玲,魏品康,张申.消痰破瘀复方对小鼠黑色素瘤肺转移及血粘度的影响[J].中国中西医结合杂志.2007,中医基础特集:68-69.
[39]徐立春,陈志琳,孙振华.白藜芦醇对恶性黑色素瘤生长抑制作用的体外及体内研究[J].南京医科大学学报.2009,29(6):790-793.
[40]王莉平,王义善,张国营.狼毒对恶性黑色素瘤细胞生长的影响及其分子作用机制的研究[J].时珍国医国药.2011,22(5):1133-1135.
[41] Zhao J, Qi Q, Yang Y, et al．Inhibition of alpha(4) integrin mediated: adhesion was involvedin the reduction of B16-F10melanoma cells lung colonization in C57BL/6mice treated withgambogic acid[J]. Eur J Pharmacol.2008,5(89):127-131.
[42]祝柏芳.五虎丹外敷加BCG前臂划痕洽疗皮肤恶性黑色素瘤9例[J].辽宁中医杂志.1992,19(2):32-33.
[43]张永祥,梁喜爱.茯苓拔毒散等治疗溃疡性黑色素瘤10例报告[J].中西医结合杂志.1986,6(11):697.
[44]段桂卿.中医治疗恶性黑色素瘤三例[J].南京中医学院学报.1986,(4):22.
[45]姜毅,朱丽文.治疗恶性黑色素瘤1例体会[J].中国民间疗法.2000,8(4):6-7.
[46]刘少翔,侯浚,高良.鸦乳为主综合治疗晚期恶性肿瘤疗效观察[J].河北中医.1991,18(6):4.
[47]梅玉屏,曾星,黄羽等.重组卡介苗及猪苓多糖对荷瘤小鼠巨噬细胞NO释放量的影响[J].分子与免疫学杂志.2002,18(3):292-295.
[48]李炳生,陈秀华,任文龙.康莱特注射液的抗肿瘤作用[J].中国医药工业杂志.1998,29(10):456-458.
[49]]桂飞,马伟峰,蔡绍晖等.姜黄素抗小鼠黑色素瘤分子机制的初步研究[J].中药材.2008,31(11):1685-1689.
[50]杜标炎,袁静,谭宇蕙.六味地黄丸对自杀基因系统治疗黑色素瘤的增效作用[J].广州中医药大学学报.2006,23(5):397-402.
[1]Kitchens CA, McDonald PR, Shun TY, et al. Identification of Chemosensitivity Nodes forVinblastine through Small Interfering RNA High-Throughput Screens[J]. Pharmacol Exp Ther.201,3(39):851-858.
[2]Stegh AH, Brennan C, Mahoney JA, et al. Glioma oncoprotein Bcl2L12inhibits the p53tumorsuppressor[J]. Genes Dev.2010,24(21):194-204.
[3]Ferreira AK, Meneguelo R, Marques FL, et al.Synthetic phosphoethanolamine a precursor ofmembrane phospholipids reduce tumor growth in mice bearing melanoma B16-F10and in vitroinduce apoptosis and arrest in G2/M phase[J].Biomed Pharmacother.2012,66(7):541-548.
[4]Duh PD, Chen ZT, Lee SW, et al.Antiproliferative activity and apoptosis induction ofEucalyptus Citriodora resin and its major bioactive compound in melanoma B16F10cells[J].AgricFood Chem.2012,560(32):7866-7872.
[5]Fai o-Flores F, Suarez JA, Soto-Cerrato V, et al.Bcl-2family proteins and cytoskeleton changesinvolved in DM-1cytotoxic effect on melanoma cells[J].Tumour Biol.2013,23(5):6-7.
[6]Arbab IA, Looi CY, Abdul AB, et al. Dentatin Induces Apoptosis in Prostate Cancer Cells viaBcl-2, Bcl-xL, Survivin Downregulation, Caspase-9,-3/7Activation, and NF-κB Inhibition[J].Evid Based Complement Alternat Med2012,20(12):1-15.
[7]Lee SJ, Cho SC, Lee EJ, et al. Interleukin-20Promotes Migration of Bladder Cancer Cellsthrough Extracellular Signal-regulated Kinase (ERK)-mediated MMP-9Protein ExpressionLeading to Nuclear Factor (NF-κB) Activation by Inducing the Up-regulation of p21WAF1ProteinExpression[J].Biol Chem.2013,288(8):539-542.
[8]Li G, Zhang Y, Qian Y, et al. Interleukin-17A promotes rheumatoid arthritis synoviocytesmigration and invasion under hypoxia by increasing MMP2and MMP9expression throughNF-κB/HIF-1α pathway[J]. Mol Immunol.2013,3(3):237-236.
[9]Siveen KS, Kuttan G.Inhibition of B16F-10melanoma-induced lung metastasis in C57BL/6mice by Aerva lanata via induction of apoptosis.Integr Cancer Ther.2013,12(1):81-92.
[10]陈奇.中药药理研究方法学[M].上海;上海人民卫生出版社，1993:76-77.
[11]李仪奎,吴健宇.血清药理实验中采血时间的通法方案[J].中国药理学通报.1999,15(6):569-570.
[12]王国佐,葛金文.血清药理学方法在中药研究中的进展[J].湖南中医药大学学报.2007,27(3):78-80.
[13]郭志梅,钱新华.诱导K562细胞向红系分化的中药血清药理学方法探讨[J].解放军药学学报.2005,5(21):17-20.
[14]刘雅男,娄建石,赵振宇等.血清药理学方法研究复方中药对B16黑素瘤细胞黑素合成的影响[J].中国中西医结合皮肤性病学杂志.2005,4(3):155-157.
[15]吴健宇,李仪奎,符胜光.补阳还五汤保护自由基损伤血管内皮细胞的血清药理实验方法的建立[J].中药药理与临床.1999,15(1):45-46.
[16]马腾,刘学政,刘丽波等.人血管生成素1的克隆、序列分析和单酶切法构建毕氏酵母表达载体[J].中国组织工程研究与临床康.2007,11(6):1041-1044,1048.
[17]陈华江,王杰军.基质金属蛋白酶的结构及其调节机制[J].国外医学(肿瘤学分册).2001,28(1):20-23.
[18]Kaltschmidt B, Widera D, Kaltschmidt C. Signaling via NF-kappaB in the nervous system[J].Biochim Biophys Acta.2005,1745(3):287-299.
[19]Arbab IA, Looi CY, Abdul AB,et al.Dentatin Induces Apoptosis in Prostate Cancer Cells viaBcl-2, Bcl-xL, Survivin Downregulation, Caspase-9,-3/7Activation, and NF-κB Inhibition[J].EvidBased Complement Alternat Med.2012,8(5):60.
[20]Lee SJ, Cho SC, Lee EJ,et al.Interleukin-20promotes migration of bladder cancer cells throughERK-mediated MMP-9expression leading to NF-kB activation by inducing the up-regulation ofp21WAF1expression[J].Biol Chem.2012,10(1):27.
[21]Li G, Zhang Y, Qian Y, et al.Interleukin-17A promotes rheumatoid arthritis synoviocytesmigration and invasion under hypoxia by increasing MMP2and MMP9expression throughNF-κB/HIF-1α pathway[J].Moman CD, Gentilcore G, Palmieri G, Ascierto PA.NF-κB as potentialtarget in the treatment of melanoma. J Transl Med.2012,(20)10:53.
[22]李中信,贾漪涛,马顺茂等.结直肠癌组织NF-κB和MMP-9表达与腹腔微转移关系的初步探讨[J].中华肿瘤防治杂志.2008,15(13):1014-1017.
[23]唐汉钧.乳腺癌中的中医临床与实验研究[J].中医药学刊.2003,21(2):168-172
[24]胡作为,周燕萍.肺主皮毛及其现代免疫学基础刍议[J].辽宁中医志.2004,31(3):200.
[25]王颖晓.肺主皮毛理论的研究进展[J].上海中医药杂志.2006,40(1):62-64.
[26]唐定书,杨晓华.谈“肺主皮毛”理论在皮肤病治疗中的应用[J].四川中医.2008,26(3):43.
[27]汪波,丁德秭.四君子汤合沙参麦冬汤加减配合化疗治疗中晚期非小细胞肺癌临床观察[J].世界中西医结合杂志.2009,4(8):564-566.
[28]丁纪元,孟昭琳.黄芪四君子汤在晚期非小细胞肺癌化疗中的应用[J].浙江中西医结合杂志.2006,16(1):28-29.
[29]赖义勤,陈乃杰,吴丹红等.温胆汤合四君子汤配合化疗治疗晚期非小细胞肺癌29例[J].福建中医药.2011,6(42):13-14.
[30]沈晨君.中药治疗肺癌用药规律分析[J].山东中医药大学学报.2011,35(2):127-129.
[31]杨柱,陈学习.肿瘤的中医病因病机初探[J].辽宁中医杂.2002,4(29):197.
[32]尤建良.恶性黑色素瘤验案三则[J].四川中医.2006,24(1):69-70.
[33]牛国晓,李洁.半枝莲抗肿瘤机制研究进展[J].肿瘤防治研究.2012,39(2):232.
[34]阎晓天,李雁.中医治疗皮肤癌临床及实验研究概况[J].中国中医药科技.1997,4(5)：322.
[35]Cannon MJ, Goyne HE, Stone PJ, et al. Modulation of p38MAPK signaling enhances dendriticcell activation of human CD4(+) Th17responses to ovarian tumor antigen[J]. Cancer ImmunolImmunother.2013,1(1):25.
[36] Zhang Y, Chaux P, Stroobant V, et al. A MAGE-3peptide presented by HLA-DR1to CD4+Tcells that were isolated from a melanoma patient vaccinated with a MAGE-3protein[J].Immunol.2003,171(1):219-225.
[37]白黎智,姜志良,王林等.黑色素瘤抗原基因-1,3基因在肺癌组织中的表达及其意义[J].临床军医杂志.2005,33(3):294-296.
[38]燕振忠.黑素瘤抗原-3基因及蛋白在非小细胞肺癌中的表达[J].滨州医学院学报.2008,31(5):350.
[39]巴月,吴逸明,陈琛.肺癌的免疫治疗肿瘤防治杂志[J].2002,9(2):200-201.
[40]王长秀,马润娣,于立坚.土贝母苷甲对小鼠B16黑色素瘤和Lewis肺癌转移的抑制作用[J].中国临床药理学与治疗学.2006,11(7):764-770.
[41]陈旭,王娟,蒋晓山等.莪术醇对肺癌A549细胞凋亡诱导因子、聚ADP核糖聚合酶及Caspase-3表达的影响[J].中国实验方剂学杂志.2011,17(19):157-159.
[42]夏卫军,程罗根,徐建亚等.莪术对黑色素瘤细胞转移相关能力的影响[J].中药药理与临床.2007,23(2):45-47.
[43]代志军,刘小旭,汤薇等.半枝莲提取物对H22荷瘤小鼠免疫功能的影响及其抑瘤作用[J].南方医科大学学报.2008,28(10):1835-1837.
[44]田代真一.“血清药理学”と“血清药化学”———汉方の药理学がい始まつた药物血中浓度测定の新しい世界[J]. TDM研究.1988,(5):54.
[45]杨彦芳,王玉芹.中药复方血清药理学方法规范化探讨[J].中国中西医结合杂志.2000,20(5):380-382.
[46]Iwama H, Amagaya S, Ogihara Y. Effect of shosaikoto, a Japanese and Chinese traditionalherbal medicinal mixture, on the mitogenic activity of lipopolysaccharide:a new pharmacologicaltesting method[J]. Ethnopharmacol.1987,21(1):45-53.
[47]高月,吕秋军,刘永学等.中药复方物质基础的研究[J].中国新药杂志.2000,9(5):307-308。
[48]王淑杰,张秀英,卢立波.中药血清药理学的研究方法及其应用[J].中国兽药杂志.2008,38(3):35-37,29.
[49]张铭杰,高辉,刘小雷.中药血清药理学的研究方法与进展[J].北方药学.2006,3(2):50-52.
[50]赵婷秀,陈振发.中药血清药理学方法的研究现状[J].湖北中医学院学报.2003,5(3):45-46.
[51]詹红生.含药血清实验方法及其在中药新药研制中应用展望[J].浙江中医院学报.2000，24:79-82.
[52]徐海波,吴清和.中药血清药理学实验方法的探讨[J].中国中医药科技.2000,7(1):43-44.
[53]王国佐.血清药理学方法在中药研究中的进展[J].湖南中医药大学学报.2007,27(3):78-80.
[54]李仪奎.中药血清药理学实验方法的若干问题[J]．中药新药与临床药理.1999,10(2):96-99.
[55]王力倩,李仪奎,符胜光等.血清药理学方法研究探索[J].中药药理与临床.1997,13(3):29-31.
[56]王力倩,余上才,李仪奎.用血清药理学方法研究中药苦参、仙鹤草的抗肿瘤作用[J].中国中医药科技.1995,2(5):19-21.
[57]王宁生.关于血清药理学的若干思考[J].中国新药与临床药理.1999,10(5):263-266.
[58]黄臣虎,陆茵,高骁君等.中药血清药理学研究进展[J].中国新药与临床药理2011,17(10):266-271.
[59]包金凤,刘国卿.中药血清药理学的方法学研究概述[J].药学进展,2000,24(2):89-92.
[60]詹红生,赵咏芳,冯伟等.含药血清方法在中药调节骨与软骨代谢基础研究中的应用[J].中国骨伤.2000,13(11):661-662.
[61]王霖,张云,汪受传.中药血清药理学研究中含药血清添加量问题的商榷[J].山西中医.2006,22(1):51-52.
[62]潘卫松,刘美凤,石钺等.血清药理学、血清化学和中药药代动力学[J].世界科学技术-中药现代化.2002,4(3):53-56.
[63]崔玲,晏卫东.中药血清药理研究方法回顾与展望[J].武警学.2004,15(6):460-461.
[64]陶正鹏,冯秋珍,徐建民.四君子汤含药血清抑癌作用的实验研究[J].湖北中医杂志.2006,28(9):9-10.
[65]刘玉红.四君子汤复方总多糖的体外抗肿瘤和免疫活性研究[J].食品与药品.2009,11(5):22-23.
[66]李传刚,李墨林,舒晓宏等.四君子汤通过Fas受体诱导小鼠膀胱癌细胞凋亡[J].肿瘤防治杂志.2005,12(20):1539-1541.
[67]赵爱光,杨金坤,赵海磊等.四君子汤诱导裸小鼠移植性人胃癌细胞凋亡的初步研究[J].癌症.2001,20(2):164-167.
[68]李亚平,钟加滕,张志超等. Bcl-2抑制剂S1通过内质网途径诱导黑色素瘤B16细胞凋亡的机制[J].中国老年学杂志.2012,32(4):767-769.
[69]姜新,曲雅勤,贾晓晶等.人参皂苷Rg3抑制B16黑色素瘤生长和诱导凋亡的实验研究[J].中医学.2006,10(6):593-595.
[70]王澈,王敏伟,田代真一等.人白细胞介素1β通过Caspase途径诱导人黑色素瘤A375-S2细胞凋亡[J].中国病理生理杂志.2004,20(7):1138-1143.
[71]黄浏妓,赵刚.三氧化二砷抗肿瘤作用及其机理的研究现状和展望[J].湖北中医学院学报.2005,7(1):60-61.
[72]黄浏妓,赵刚.三氧化二砷与刺五加合用诱导细胞凋亡的实验研究[J].时珍国医国药2006,11(10):50.
[73]陈达理,黄涛.四君子汤对体外肿瘤细胞株bcl-2蛋白、MMP-2mRNA表达的作用[J].山东中医药大学学报.2004,28(6):470-472.
[74]Madonna G, Ullman CD, Gentilcore G, et al.NF-κB as potential target in the treatment ofmelanoma.[J]. Transl Med.2012,20(10):53.
[75]Song JK, Park MH, Choi DY, et al.Deficiency of C-C chemokine receptor5suppresses tumordevelopment via inactivation of NF-κB and upregulation of IL-1Ra in melanoma model[J]. PLoSOne.2012,7(5):743-747.
[76]骆殊,沈洪,朱学军等.黄芪、莪术配伍对胃癌MKN-45细胞COX-1、COX-2、NF-κB、VEGF、MMP-2表达的影响[J].现代中西医结合杂志.2009,18(4):351-353.
[77]陈治文,王东萍,夏俊等.三氧化二砷对恶性黑素瘤A375细胞NF-κB、C-IAP2及caspase-3表达的影响[J].蚌埠医学院学报.2008,33(6):728-730.
[78]马纯政.中药逆转恶性肿瘤多药耐药研究进展[J].河南中医2005,25(7):84-86.
[79]许济群,方剂学[M]．上海;上海科学技术出版社,1985:66-67.
[80]甘雨良,焦丹,刘文峰.四君子汤加减联合化疗治疗胃肠道恶性肿瘤多药耐药基因阳性病例[J].中国实验方剂学杂志.2010,16(6):253-255.
[81]蔡骏,王华,周胜等.四君子汤联合肠内营养对胃癌手术患者T细胞亚群及营养状况影响的随机对照研究[J].中国实验方剂学杂志.2008,6(1):37-40.
[82]周峰,李传刚,刘用楫.四君子汤在膀胱癌治疗中的应用及研究进展[J].大连医科大学学报.2008,30(5):473-475.
[83]李传刚,李墨林,舒晓宏等.四君子汤对膀胱癌荷瘤小鼠化疗中免疫功能的保护作用[J].大连医科大学学报.2006,28(3):164-166.
[84]王玉荣,王泽时.加味四君子汤抗小鼠宫颈癌作用的实验研究[J].山西中医学院学报.2003,4(4):12-13.
[85]裘维焰,杨锋,戴关海.四君子汤合用干扰素对荷瘤小鼠抑瘤率和免疫调节作用的影响[J].实用中医药杂志.2007,23(5):275-276.
[86]王玮琴,周惠君.中药抑制肿瘤血管生成作用的筛选模型和研究进展[J].中国临床药学杂志.2004,13(2):126-128.
[87]周劬志.中药抗肿瘤血管生成研究述略[J].中国处方药.2004,(8):30-32.
[88]薛维伟,王瑞平.中药抗肿瘤血管生成研究近况[J].江西中医学院学报.2006,18(1):64-66.
[89]梁广,李校堑,刘敏等.莪术油的药学及临床应用研究概况[J].安徽医药.2006,10(12):897-900.
[90]李昕,聂克.中药抑制肿瘤端粒酶活性的研究进展[J].中药新药与临床药理.2004,15(6):440-443.
[91]陈震,雯霞,程琳.健脾理气中药上调nm23表达[J].中国癌症杂志.2002.12(2):120-122.
[92]陈颢,陈震,屠红等.C57BL/6小鼠的血循环DNA的定量研究[J].肿瘤.2005,25(2):427-429.
[93]成文武,宋明志,薛琼等.健脾理气汤对裸鼠人肝癌高转移模型的影响[J].中华肝脏病杂志.2005,13(6):460-461.
[94]王鹏,黄雯霞,刘鲁明.健脾理气法防治肝癌的临床及实验研究概况[J].上海中医药杂志.2005,39(5):60-62.
[95]王家鹏,郭刚.中药诱导恶性肿瘤细胞分化的研究进展[J].中医研究.2003,16(2):48-51.
[96]刘玉红四君子汤复方总多糖的体外抗肿瘤和免疫活性研究[J].食品与药品.2009,11(5):22-23.
[97]曾艳兵,张妮娜,卜平.中药对恶性肿瘤细胞信号转导通路的影响及其作用机理研究的进展[J].中国中西医结合杂志.2004,24(7):670-672.
[98]赵爱光,杨金坤,尤圣富等.中药WCA对人胃癌细胞SGC-7901体内作用[J].中国中药杂志.2007,32(19):2028-2030.
[99]陈达理,黄涛.四君子汤对荷瘤小鼠抑瘤和诱导肿瘤细胞凋亡的实验研究[J].山东中医杂志.2005,23(4):228-229.
[100]李传刚,李墨林,舒晓宏等.四君子汤对小鼠膀耽癌化疗的减毒增效作用[J].中国中西医结合杂志.2005,25(4):35-357.
[101]金岩,李海波,关洪全等.中药诱导肿瘤细胞凋亡机制的研究进展[J].中医研究.2005,18(3):52-57.
[102]李彬,宋明全.四君子汤含药血清对SGC-7901细胞株凋亡及其相关蛋白表达的影响[J].山东中医杂志.2008,27(4):262-263.
[103]赵爱光,杨金坤,赵海磊.健脾中药诱导人胃癌细胞裸鼠移植瘤细胞凋亡的研究[J].世界华人消化杂志.2000,8(7):737-740.
[104]李秋泽,董子明,赵国强.黑色素瘤抗原基因MAGE-1、MAGE-3和抑癌基因p53在肺癌中表达的研究[J]．肿瘤医学.2007,5(8):1106-1108.
[105]辛颖,姜新,崔俊生等.人参皂苷Rg3抑制B16黑色素瘤新生血管生成及其机制的探讨[J].中华肿瘤防治杂志.2010,17(8):590-593.
[106]刘基巍,陈俊霞,于丽华等.人参皂甙Rg3和核糖核酸酶抑制因子转基因对小鼠黑色素瘤的抑制作用研究[J].中华肿志.2004,26(12):722-725.
[107]谢遵江,刘文庆,贺业春等.人参多糖及IL-2对小鼠黑色素瘤细胞体内的抑制效应[J].解剖学报.2002,33(5):538-541.
[108]翁小刚.人参皂苷的生物转化物抑制鼠黑色素瘤B16-F10细胞的生长和转移[J].国外医学(中医中药分册).2002,24(1):41-42.
[109]张永祥,梁喜爱.茯苓拔毒散等治疗溃疡性黑色素瘤10例报告[J].中西医结合杂志.1986，6(87):41-45.
[110]马晶波,冯树芳,李锋等.甘草黄酮对B16黑色素瘤细胞代谢的影响[J].复旦学报(医学版).2003,30(4):353-355.
[2] Stone A, Cooper J, Koenig KL, et al.A comparison of survival rates for treatment ofmelanoma metastatic to the brain[J].Cancer Invest.2004,22(4):492-497.
[3]尤建良.恶性黑色素瘤验案三则[J].四川中医.2006,24(1):69-70.
[4]杨柱,陈学习.肿瘤的中医病因病机初探[J].中国民族民间医药杂志2002,29(4):197-198.
[5]木拉提·克扎衣别克.抗肿瘤中药的分类及作用机理[J].新疆医科大学学报.2006,29(11):1102-1104.
[6]辛颖,姜新,崔俊生等．人参皂苷Rg3抑制B16黑色素瘤新生血管生成及其机制的探讨[J].中华肿瘤防治杂志.2010,17(8):590-593.
[7]阴健译.厚朴的甲醉提取物的木兰醇对体内两期致癌试验[J].国外医学.中医中药分册19,4(3):52.
[8]陈立军,朱荃.蜂王浆冻干粉含药血清对小鼠B16BL6黑色素瘤细胞增殖的影响[J].中药药理与临床.2006,22(1):44-46.
[9]顾勤,徐建亚,程罗根等.当归对黑色素瘤细胞粘附、侵袭、运动和转移能力的影响[J].中药材.2007,30(3):302-305.
[10]陈颢,陈震,屠红等.健脾理气中药对荷B16黑色素瘤小鼠肝转移的干预作用[J].上海中医药杂志.2007,41(10):79-82.
[11]张硕.乾坤宁抗肿瘤的药效学和机理研究[D].成都:成都中医药大学,2005.
[12]汤铭新,余桂清,张代钊等.复方生脉注射液治疗恶性黑色素瘤一例[J].中医杂志.1982,10(12):67-69.
[13]吴强,姚立人.脾虚对B16黑色素瘤肺转移的影响[J].安徽医科大学学报.1991,26(2):81-84.
[14]汪海英,李福安,魏全嘉.抗肿瘤中药的研究现状[J].第青海医学院学报.2008,29(4):278-282.
[15]刘晓艳,方红,羊正纲等.苦参碱对人恶性黑素瘤细胞株侵袭能力及乙酰肝素酶mRNA表达的抑制作用[J]中药材.2006,29(3):253-256.
[16]陈红,王郡甫.金荞麦提取物抑制黑色素瘤细胞穿越内皮单层的机制研究[D].山东:山东省医学科学院,2010.
[17]徐立春,陈志琳,孙振华.穿心莲提取物协同人恶黑TIL抗肿瘤的研究[J].肿瘤学报.2001,21(4):255-256.
[18]毕黎琦,李红军,张玉华．中药天花粉蛋白对黑色素瘤细胞凋亡及细胞周期的影响[J]．中国中西医结合杂志.1998,18(1):35-37.
[19]杨娴,刘汝青,杜德荣.白花蛇舌草总黄酮对黑色素瘤A375和B16细胞增殖抑制作用的研究[J].世界中西医结合杂志.2011,6(10):844-846,856.
[20]左海军,李丹,吴斌等.冬凌草的化学成分及其抗肿瘤活性[J].沈阳药科大学学报.2005,22(4):258-261.
[21]陈龙邦,王靖华,臧静等.南β-榄香烯诱导小鼠黑色素瘤B16细胞凋亡的研究[J].金陵医院学报.1992,12(1):48-49.
[22]徐立春,孙振华,陈志琳等.三棱、莪术提取物修饰的肿瘤细胞疫苗的非特异性抗瘤实验研究[J].癌症.2002,20(12):1380-1382.
[23]陈培丰,刘鲁明,陈震等.恶性肿瘤肝转移血瘀证与参三七、丹参干预作用的研究[J].浙江中医药大学学报.2007,31(5):552-553.
[24]杨庆伟,刘延庆,戴小军等.南蛇藤对鼠黑色素瘤B16BL6细胞增殖抑制及凋亡诱导作用研究[J].中药药理与临床.2008,24(3):61-63.
[25] WZ Zhao, HY Liu, SF Xu, et al．Migration and metalloproteinases determine the invasivepotential of mousemelanoma cells,but not melanin and telomerase[J].CancerLetters,2001,16(2):49-55.
[26]徐建亚,顾勤,夏卫军等.丹参对小鼠黑色素瘤细胞株B16-BL6侵袭和转移能力的影响[J].中国中医药信息杂志.2007,14(6):26-28.
[27]夏卫军,程罗根,徐建亚等.莪术对黑色素瘤细胞转移相关能力的影响[J].中药药理与临床.2007,23(2):45-47.
[28]徐建亚,顾勤,夏卫军.鸡血藤对黑色素瘤细胞黏附、侵袭、运动和转移能力的影响[J].中药材.2006,33(10):1595-1599.
[29]邱侠,杨振江,赵霞等.髓清丸对黑色素瘤VEGF MMP-2基因表达的影响[J].中医药学刊.2004,22(6):1042-1043.
[30]杨振江,赵霞,刘兵.髓清丸对裸小鼠黑色素瘤B16自发性肺转移影响的研究[J].成都中医药学报.2004,27(2):30-32.
[31]张英,张勇,黄会英.山仙颗粒对小鼠黑色素瘤肺转移中IL-2水平的影响[J].陕西中医学院学报.2004,27(3):63-64.
[32]王希胜,张英,陈光伟.山仙颗粒对小鼠黑色素瘤肺转移中NM23/NDPK水平的影响[J].陕西中医.2006,27(2):244-245.
[33]王淑美,徐晓玉,陈刚等.桃红四物汤Ⅱ号抑制小鼠B16黑色素瘤生长及VEGF,KDR／FLK-1表达[J].中国中药杂志.2005,30(23):1866-1869.
[34]郑广娟,张丹,张静.中药启乐抗肿瘤转移作用研究.医学研究通迅[J].2003,32(7):61-62.
[35]鲁向明,王仲,陈景三等.川芎嗪诱导iNOS和NO表达抗荷黑色素瘤鼠肺转移[J].2006,16(21):3208-3210.
[36]刘锦蓉,叶松柏.川芎嗪抗肿瘤转移作用及其机理.中国药理学与毒理学杂志[J].1993,7(2):149-150.
[37]王长秀,马润娣,于立坚.土贝母苷甲对小鼠B16黑色素瘤和Lewis肺癌转移的抑制作用[J].中国临床药理学与治疗学.2006,1(7):764-770.
[38]许玲,魏品康,张申.消痰破瘀复方对小鼠黑色素瘤肺转移及血粘度的影响[J].中国中西医结合杂志.2007,中医基础特集:68-69.
[39]徐立春,陈志琳,孙振华.白藜芦醇对恶性黑色素瘤生长抑制作用的体外及体内研究[J].南京医科大学学报.2009,29(6):790-793.
[40]王莉平,王义善,张国营.狼毒对恶性黑色素瘤细胞生长的影响及其分子作用机制的研究[J].时珍国医国药.2011,22(5):1133-1135.
[41] Zhao J, Qi Q, Yang Y, et al．Inhibition of alpha(4) integrin mediated: adhesion was involvedin the reduction of B16-F10melanoma cells lung colonization in C57BL/6mice treated withgambogic acid[J]. Eur J Pharmacol.2008,5(89):127-131.
[42]祝柏芳.五虎丹外敷加BCG前臂划痕洽疗皮肤恶性黑色素瘤9例[J].辽宁中医杂志.1992,19(2):32-33.
[43]张永祥,梁喜爱.茯苓拔毒散等治疗溃疡性黑色素瘤10例报告[J].中西医结合杂志.1986,6(11):697.
[44]段桂卿.中医治疗恶性黑色素瘤三例[J].南京中医学院学报.1986,(4):22.
[45]姜毅,朱丽文.治疗恶性黑色素瘤1例体会[J].中国民间疗法.2000,8(4):6-7.
[46]刘少翔,侯浚,高良.鸦乳为主综合治疗晚期恶性肿瘤疗效观察[J].河北中医.1991,18(6):4.
[47]梅玉屏,曾星,黄羽等.重组卡介苗及猪苓多糖对荷瘤小鼠巨噬细胞NO释放量的影响[J].分子与免疫学杂志.2002,18(3):292-295.
[48]李炳生,陈秀华,任文龙.康莱特注射液的抗肿瘤作用[J].中国医药工业杂志.1998,29(10):456-458.
[49]]桂飞,马伟峰,蔡绍晖等.姜黄素抗小鼠黑色素瘤分子机制的初步研究[J].中药材.2008,31(11):1685-1689.
[50]杜标炎,袁静,谭宇蕙.六味地黄丸对自杀基因系统治疗黑色素瘤的增效作用[J].广州中医药大学学报.2006,23(5):397-402.
[1]Kitchens CA, McDonald PR, Shun TY, et al. Identification of Chemosensitivity Nodes forVinblastine through Small Interfering RNA High-Throughput Screens[J]. Pharmacol Exp Ther.201,3(39):851-858.
[2]Stegh AH, Brennan C, Mahoney JA, et al. Glioma oncoprotein Bcl2L12inhibits the p53tumorsuppressor[J]. Genes Dev.2010,24(21):194-204.
[3]Ferreira AK, Meneguelo R, Marques FL, et al.Synthetic phosphoethanolamine a precursor ofmembrane phospholipids reduce tumor growth in mice bearing melanoma B16-F10and in vitroinduce apoptosis and arrest in G2/M phase[J].Biomed Pharmacother.2012,66(7):541-548.
[4]Duh PD, Chen ZT, Lee SW, et al.Antiproliferative activity and apoptosis induction ofEucalyptus Citriodora resin and its major bioactive compound in melanoma B16F10cells[J].AgricFood Chem.2012,560(32):7866-7872.
[5]Fai o-Flores F, Suarez JA, Soto-Cerrato V, et al.Bcl-2family proteins and cytoskeleton changesinvolved in DM-1cytotoxic effect on melanoma cells[J].Tumour Biol.2013,23(5):6-7.
[6]Arbab IA, Looi CY, Abdul AB, et al. Dentatin Induces Apoptosis in Prostate Cancer Cells viaBcl-2, Bcl-xL, Survivin Downregulation, Caspase-9,-3/7Activation, and NF-κB Inhibition[J].Evid Based Complement Alternat Med2012,20(12):1-15.
[7]Lee SJ, Cho SC, Lee EJ, et al. Interleukin-20Promotes Migration of Bladder Cancer Cellsthrough Extracellular Signal-regulated Kinase (ERK)-mediated MMP-9Protein ExpressionLeading to Nuclear Factor (NF-κB) Activation by Inducing the Up-regulation of p21WAF1ProteinExpression[J].Biol Chem.2013,288(8):539-542.
[8]Li G, Zhang Y, Qian Y, et al. Interleukin-17A promotes rheumatoid arthritis synoviocytesmigration and invasion under hypoxia by increasing MMP2and MMP9expression throughNF-κB/HIF-1α pathway[J]. Mol Immunol.2013,3(3):237-236.
[9]Siveen KS, Kuttan G.Inhibition of B16F-10melanoma-induced lung metastasis in C57BL/6mice by Aerva lanata via induction of apoptosis.Integr Cancer Ther.2013,12(1):81-92.
[10]陈奇.中药药理研究方法学[M].上海;上海人民卫生出版社，1993:76-77.
[11]李仪奎,吴健宇.血清药理实验中采血时间的通法方案[J].中国药理学通报.1999,15(6):569-570.
[12]王国佐,葛金文.血清药理学方法在中药研究中的进展[J].湖南中医药大学学报.2007,27(3):78-80.
[13]郭志梅,钱新华.诱导K562细胞向红系分化的中药血清药理学方法探讨[J].解放军药学学报.2005,5(21):17-20.
[14]刘雅男,娄建石,赵振宇等.血清药理学方法研究复方中药对B16黑素瘤细胞黑素合成的影响[J].中国中西医结合皮肤性病学杂志.2005,4(3):155-157.
[15]吴健宇,李仪奎,符胜光.补阳还五汤保护自由基损伤血管内皮细胞的血清药理实验方法的建立[J].中药药理与临床.1999,15(1):45-46.
[16]马腾,刘学政,刘丽波等.人血管生成素1的克隆、序列分析和单酶切法构建毕氏酵母表达载体[J].中国组织工程研究与临床康.2007,11(6):1041-1044,1048.
[17]陈华江,王杰军.基质金属蛋白酶的结构及其调节机制[J].国外医学(肿瘤学分册).2001,28(1):20-23.
[18]Kaltschmidt B, Widera D, Kaltschmidt C. Signaling via NF-kappaB in the nervous system[J].Biochim Biophys Acta.2005,1745(3):287-299.
[19]Arbab IA, Looi CY, Abdul AB,et al.Dentatin Induces Apoptosis in Prostate Cancer Cells viaBcl-2, Bcl-xL, Survivin Downregulation, Caspase-9,-3/7Activation, and NF-κB Inhibition[J].EvidBased Complement Alternat Med.2012,8(5):60.
[20]Lee SJ, Cho SC, Lee EJ,et al.Interleukin-20promotes migration of bladder cancer cells throughERK-mediated MMP-9expression leading to NF-kB activation by inducing the up-regulation ofp21WAF1expression[J].Biol Chem.2012,10(1):27.
[21]Li G, Zhang Y, Qian Y, et al.Interleukin-17A promotes rheumatoid arthritis synoviocytesmigration and invasion under hypoxia by increasing MMP2and MMP9expression throughNF-κB/HIF-1α pathway[J].Moman CD, Gentilcore G, Palmieri G, Ascierto PA.NF-κB as potentialtarget in the treatment of melanoma. J Transl Med.2012,(20)10:53.
[22]李中信,贾漪涛,马顺茂等.结直肠癌组织NF-κB和MMP-9表达与腹腔微转移关系的初步探讨[J].中华肿瘤防治杂志.2008,15(13):1014-1017.
[23]唐汉钧.乳腺癌中的中医临床与实验研究[J].中医药学刊.2003,21(2):168-172
[24]胡作为,周燕萍.肺主皮毛及其现代免疫学基础刍议[J].辽宁中医志.2004,31(3):200.
[25]王颖晓.肺主皮毛理论的研究进展[J].上海中医药杂志.2006,40(1):62-64.
[26]唐定书,杨晓华.谈“肺主皮毛”理论在皮肤病治疗中的应用[J].四川中医.2008,26(3):43.
[27]汪波,丁德秭.四君子汤合沙参麦冬汤加减配合化疗治疗中晚期非小细胞肺癌临床观察[J].世界中西医结合杂志.2009,4(8):564-566.
[28]丁纪元,孟昭琳.黄芪四君子汤在晚期非小细胞肺癌化疗中的应用[J].浙江中西医结合杂志.2006,16(1):28-29.
[29]赖义勤,陈乃杰,吴丹红等.温胆汤合四君子汤配合化疗治疗晚期非小细胞肺癌29例[J].福建中医药.2011,6(42):13-14.
[30]沈晨君.中药治疗肺癌用药规律分析[J].山东中医药大学学报.2011,35(2):127-129.
[31]杨柱,陈学习.肿瘤的中医病因病机初探[J].辽宁中医杂.2002,4(29):197.
[32]尤建良.恶性黑色素瘤验案三则[J].四川中医.2006,24(1):69-70.
[33]牛国晓,李洁.半枝莲抗肿瘤机制研究进展[J].肿瘤防治研究.2012,39(2):232.
[34]阎晓天,李雁.中医治疗皮肤癌临床及实验研究概况[J].中国中医药科技.1997,4(5)：322.
[35]Cannon MJ, Goyne HE, Stone PJ, et al. Modulation of p38MAPK signaling enhances dendriticcell activation of human CD4(+) Th17responses to ovarian tumor antigen[J]. Cancer ImmunolImmunother.2013,1(1):25.
[36] Zhang Y, Chaux P, Stroobant V, et al. A MAGE-3peptide presented by HLA-DR1to CD4+Tcells that were isolated from a melanoma patient vaccinated with a MAGE-3protein[J].Immunol.2003,171(1):219-225.
[37]白黎智,姜志良,王林等.黑色素瘤抗原基因-1,3基因在肺癌组织中的表达及其意义[J].临床军医杂志.2005,33(3):294-296.
[38]燕振忠.黑素瘤抗原-3基因及蛋白在非小细胞肺癌中的表达[J].滨州医学院学报.2008,31(5):350.
[39]巴月,吴逸明,陈琛.肺癌的免疫治疗肿瘤防治杂志[J].2002,9(2):200-201.
[40]王长秀,马润娣,于立坚.土贝母苷甲对小鼠B16黑色素瘤和Lewis肺癌转移的抑制作用[J].中国临床药理学与治疗学.2006,11(7):764-770.
[41]陈旭,王娟,蒋晓山等.莪术醇对肺癌A549细胞凋亡诱导因子、聚ADP核糖聚合酶及Caspase-3表达的影响[J].中国实验方剂学杂志.2011,17(19):157-159.
[42]夏卫军,程罗根,徐建亚等.莪术对黑色素瘤细胞转移相关能力的影响[J].中药药理与临床.2007,23(2):45-47.
[43]代志军,刘小旭,汤薇等.半枝莲提取物对H22荷瘤小鼠免疫功能的影响及其抑瘤作用[J].南方医科大学学报.2008,28(10):1835-1837.
[44]田代真一.“血清药理学”と“血清药化学”———汉方の药理学がい始まつた药物血中浓度测定の新しい世界[J]. TDM研究.1988,(5):54.
[45]杨彦芳,王玉芹.中药复方血清药理学方法规范化探讨[J].中国中西医结合杂志.2000,20(5):380-382.
[46]Iwama H, Amagaya S, Ogihara Y. Effect of shosaikoto, a Japanese and Chinese traditionalherbal medicinal mixture, on the mitogenic activity of lipopolysaccharide:a new pharmacologicaltesting method[J]. Ethnopharmacol.1987,21(1):45-53.
[47]高月,吕秋军,刘永学等.中药复方物质基础的研究[J].中国新药杂志.2000,9(5):307-308。
[48]王淑杰,张秀英,卢立波.中药血清药理学的研究方法及其应用[J].中国兽药杂志.2008,38(3):35-37,29.
[49]张铭杰,高辉,刘小雷.中药血清药理学的研究方法与进展[J].北方药学.2006,3(2):50-52.
[50]赵婷秀,陈振发.中药血清药理学方法的研究现状[J].湖北中医学院学报.2003,5(3):45-46.
[51]詹红生.含药血清实验方法及其在中药新药研制中应用展望[J].浙江中医院学报.2000，24:79-82.
[52]徐海波,吴清和.中药血清药理学实验方法的探讨[J].中国中医药科技.2000,7(1):43-44.
[53]王国佐.血清药理学方法在中药研究中的进展[J].湖南中医药大学学报.2007,27(3):78-80.
[54]李仪奎.中药血清药理学实验方法的若干问题[J]．中药新药与临床药理.1999,10(2):96-99.
[55]王力倩,李仪奎,符胜光等.血清药理学方法研究探索[J].中药药理与临床.1997,13(3):29-31.
[56]王力倩,余上才,李仪奎.用血清药理学方法研究中药苦参、仙鹤草的抗肿瘤作用[J].中国中医药科技.1995,2(5):19-21.
[57]王宁生.关于血清药理学的若干思考[J].中国新药与临床药理.1999,10(5):263-266.
[58]黄臣虎,陆茵,高骁君等.中药血清药理学研究进展[J].中国新药与临床药理2011,17(10):266-271.
[59]包金凤,刘国卿.中药血清药理学的方法学研究概述[J].药学进展,2000,24(2):89-92.
[60]詹红生,赵咏芳,冯伟等.含药血清方法在中药调节骨与软骨代谢基础研究中的应用[J].中国骨伤.2000,13(11):661-662.
[61]王霖,张云,汪受传.中药血清药理学研究中含药血清添加量问题的商榷[J].山西中医.2006,22(1):51-52.
[62]潘卫松,刘美凤,石钺等.血清药理学、血清化学和中药药代动力学[J].世界科学技术-中药现代化.2002,4(3):53-56.
[63]崔玲,晏卫东.中药血清药理研究方法回顾与展望[J].武警学.2004,15(6):460-461.
[64]陶正鹏,冯秋珍,徐建民.四君子汤含药血清抑癌作用的实验研究[J].湖北中医杂志.2006,28(9):9-10.
[65]刘玉红.四君子汤复方总多糖的体外抗肿瘤和免疫活性研究[J].食品与药品.2009,11(5):22-23.
[66]李传刚,李墨林,舒晓宏等.四君子汤通过Fas受体诱导小鼠膀胱癌细胞凋亡[J].肿瘤防治杂志.2005,12(20):1539-1541.
[67]赵爱光,杨金坤,赵海磊等.四君子汤诱导裸小鼠移植性人胃癌细胞凋亡的初步研究[J].癌症.2001,20(2):164-167.
[68]李亚平,钟加滕,张志超等. Bcl-2抑制剂S1通过内质网途径诱导黑色素瘤B16细胞凋亡的机制[J].中国老年学杂志.2012,32(4):767-769.
[69]姜新,曲雅勤,贾晓晶等.人参皂苷Rg3抑制B16黑色素瘤生长和诱导凋亡的实验研究[J].中医学.2006,10(6):593-595.
[70]王澈,王敏伟,田代真一等.人白细胞介素1β通过Caspase途径诱导人黑色素瘤A375-S2细胞凋亡[J].中国病理生理杂志.2004,20(7):1138-1143.
[71]黄浏妓,赵刚.三氧化二砷抗肿瘤作用及其机理的研究现状和展望[J].湖北中医学院学报.2005,7(1):60-61.
[72]黄浏妓,赵刚.三氧化二砷与刺五加合用诱导细胞凋亡的实验研究[J].时珍国医国药2006,11(10):50.
[73]陈达理,黄涛.四君子汤对体外肿瘤细胞株bcl-2蛋白、MMP-2mRNA表达的作用[J].山东中医药大学学报.2004,28(6):470-472.
[74]Madonna G, Ullman CD, Gentilcore G, et al.NF-κB as potential target in the treatment ofmelanoma.[J]. Transl Med.2012,20(10):53.
[75]Song JK, Park MH, Choi DY, et al.Deficiency of C-C chemokine receptor5suppresses tumordevelopment via inactivation of NF-κB and upregulation of IL-1Ra in melanoma model[J]. PLoSOne.2012,7(5):743-747.
[76]骆殊,沈洪,朱学军等.黄芪、莪术配伍对胃癌MKN-45细胞COX-1、COX-2、NF-κB、VEGF、MMP-2表达的影响[J].现代中西医结合杂志.2009,18(4):351-353.
[77]陈治文,王东萍,夏俊等.三氧化二砷对恶性黑素瘤A375细胞NF-κB、C-IAP2及caspase-3表达的影响[J].蚌埠医学院学报.2008,33(6):728-730.
[78]马纯政.中药逆转恶性肿瘤多药耐药研究进展[J].河南中医2005,25(7):84-86.
[79]许济群,方剂学[M]．上海;上海科学技术出版社,1985:66-67.
[80]甘雨良,焦丹,刘文峰.四君子汤加减联合化疗治疗胃肠道恶性肿瘤多药耐药基因阳性病例[J].中国实验方剂学杂志.2010,16(6):253-255.
[81]蔡骏,王华,周胜等.四君子汤联合肠内营养对胃癌手术患者T细胞亚群及营养状况影响的随机对照研究[J].中国实验方剂学杂志.2008,6(1):37-40.
[82]周峰,李传刚,刘用楫.四君子汤在膀胱癌治疗中的应用及研究进展[J].大连医科大学学报.2008,30(5):473-475.
[83]李传刚,李墨林,舒晓宏等.四君子汤对膀胱癌荷瘤小鼠化疗中免疫功能的保护作用[J].大连医科大学学报.2006,28(3):164-166.
[84]王玉荣,王泽时.加味四君子汤抗小鼠宫颈癌作用的实验研究[J].山西中医学院学报.2003,4(4):12-13.
[85]裘维焰,杨锋,戴关海.四君子汤合用干扰素对荷瘤小鼠抑瘤率和免疫调节作用的影响[J].实用中医药杂志.2007,23(5):275-276.
[86]王玮琴,周惠君.中药抑制肿瘤血管生成作用的筛选模型和研究进展[J].中国临床药学杂志.2004,13(2):126-128.
[87]周劬志.中药抗肿瘤血管生成研究述略[J].中国处方药.2004,(8):30-32.
[88]薛维伟,王瑞平.中药抗肿瘤血管生成研究近况[J].江西中医学院学报.2006,18(1):64-66.
[89]梁广,李校堑,刘敏等.莪术油的药学及临床应用研究概况[J].安徽医药.2006,10(12):897-900.
[90]李昕,聂克.中药抑制肿瘤端粒酶活性的研究进展[J].中药新药与临床药理.2004,15(6):440-443.
[91]陈震,雯霞,程琳.健脾理气中药上调nm23表达[J].中国癌症杂志.2002.12(2):120-122.
[92]陈颢,陈震,屠红等.C57BL/6小鼠的血循环DNA的定量研究[J].肿瘤.2005,25(2):427-429.
[93]成文武,宋明志,薛琼等.健脾理气汤对裸鼠人肝癌高转移模型的影响[J].中华肝脏病杂志.2005,13(6):460-461.
[94]王鹏,黄雯霞,刘鲁明.健脾理气法防治肝癌的临床及实验研究概况[J].上海中医药杂志.2005,39(5):60-62.
[95]王家鹏,郭刚.中药诱导恶性肿瘤细胞分化的研究进展[J].中医研究.2003,16(2):48-51.
[96]刘玉红四君子汤复方总多糖的体外抗肿瘤和免疫活性研究[J].食品与药品.2009,11(5):22-23.
[97]曾艳兵,张妮娜,卜平.中药对恶性肿瘤细胞信号转导通路的影响及其作用机理研究的进展[J].中国中西医结合杂志.2004,24(7):670-672.
[98]赵爱光,杨金坤,尤圣富等.中药WCA对人胃癌细胞SGC-7901体内作用[J].中国中药杂志.2007,32(19):2028-2030.
[99]陈达理,黄涛.四君子汤对荷瘤小鼠抑瘤和诱导肿瘤细胞凋亡的实验研究[J].山东中医杂志.2005,23(4):228-229.
[100]李传刚,李墨林,舒晓宏等.四君子汤对小鼠膀耽癌化疗的减毒增效作用[J].中国中西医结合杂志.2005,25(4):35-357.
[101]金岩,李海波,关洪全等.中药诱导肿瘤细胞凋亡机制的研究进展[J].中医研究.2005,18(3):52-57.
[102]李彬,宋明全.四君子汤含药血清对SGC-7901细胞株凋亡及其相关蛋白表达的影响[J].山东中医杂志.2008,27(4):262-263.
[103]赵爱光,杨金坤,赵海磊.健脾中药诱导人胃癌细胞裸鼠移植瘤细胞凋亡的研究[J].世界华人消化杂志.2000,8(7):737-740.
[104]李秋泽,董子明,赵国强.黑色素瘤抗原基因MAGE-1、MAGE-3和抑癌基因p53在肺癌中表达的研究[J]．肿瘤医学.2007,5(8):1106-1108.
[105]辛颖,姜新,崔俊生等.人参皂苷Rg3抑制B16黑色素瘤新生血管生成及其机制的探讨[J].中华肿瘤防治杂志.2010,17(8):590-593.
[106]刘基巍,陈俊霞,于丽华等.人参皂甙Rg3和核糖核酸酶抑制因子转基因对小鼠黑色素瘤的抑制作用研究[J].中华肿志.2004,26(12):722-725.
[107]谢遵江,刘文庆,贺业春等.人参多糖及IL-2对小鼠黑色素瘤细胞体内的抑制效应[J].解剖学报.2002,33(5):538-541.
[108]翁小刚.人参皂苷的生物转化物抑制鼠黑色素瘤B16-F10细胞的生长和转移[J].国外医学(中医中药分册).2002,24(1):41-42.
[109]张永祥,梁喜爱.茯苓拔毒散等治疗溃疡性黑色素瘤10例报告[J].中西医结合杂志.1986，6(87):41-45.
[110]马晶波,冯树芳,李锋等.甘草黄酮对B16黑色素瘤细胞代谢的影响[J].复旦学报(医学版).2003,30(4):353-355.